OsteoStrata · Osteoarthritis Development Advisory
From disease complexity
to development clarity.
From osteoarthritis biology to clinical proof.
OsteoStrata is a specialist international advisory boutique helping biotechnology and pharmaceutical companies navigate the scientific, clinical, regulatory and commercial complexity of osteoarthritis development.
We integrate disease biology, precision patient strategy, biomarkers, imaging, trial design, statistics, regulation and value creation into one coherent development approach.
Independent · Senior-led · Confidential
The OsteoStrata proposition
Right mechanism. Right patient. Right evidence.
Precision strategy for osteoarthritis development — connecting disease biology, patient selection and evidence architecture into a single coherent programme.
A specialist partner for consequential decisions
Osteoarthritis programmes rarely fail for one reason.
The outcome of an osteoarthritis programme depends on the alignment of multiple decisions: mechanism, disease stage, target population, treatment-response hypothesis, biomarker strategy, imaging plan, endpoints, statistical model, regulatory pathway and future value proposition.
These decisions are frequently addressed by separate teams and vendors. We bring them together within one integrated development strategy.
Scientific rationale
01Target relevance, mechanism, tissue exposure and the relationship of biology to symptoms and structure.
Target population
02Phenotype, biological activity and disease stage translated into a credible, recruitable population.
Evidence strategy
03Endpoints, biomarkers, imaging, estimands and duration aligned with the question the programme must answer.
Regulatory pathway
04Claim, evidence package, scientific advice and a defensible position with FDA and EMA.
Development risk
05Critical assumptions, falsification criteria and the decisions that should trigger continuation, redesign or termination.
Asset value
06Differentiation, partnering relevance, reimbursement logic and the milestones that materially change value.
The Precision OA Development Framework
Precision development is not classification. It is decision architecture.
Precision development in osteoarthritis is not achieved by assigning every patient to a fixed subtype. It requires identifying the biological and clinical dimensions relevant to a specific intervention and converting them into a testable development strategy.
- 01
Mechanism
What biological process does the intervention modify?
Target relevance, tissue exposure, target engagement, pharmacodynamic plausibility and translational evidence.
- 02
Disease context
At what stage and in which form of OA is the mechanism actionable?
Early versus established disease, post-traumatic, metabolic, inflammatory activity, structural reserve and reversibility.
- 03
Patient architecture
Which combination of phenotype, biology and stage defines the population?
Clinical, structural, pain and metabolic phenotypes; biomarker and imaging profiles; progression risk and feasibility.
- 04
Theratype hypothesis
Which patients should differentially respond to this intervention?
Responder hypothesis, enrichment criteria, exclusion logic, predictive biomarker plan and falsification criteria.
- 05
Evidence architecture
What evidence is required to demonstrate the programme works?
Proof of mechanism, biology and concept; endpoints, estimands, duration, rescue and intercurrent-event strategy.
- 06
Value translation
How does evidence support approval, investment, partnering and adoption?
Regulatory claim, target product profile, investor narrative, partnering, market and health-economic alignment.
Areas of expertise
One specialist field. Integrated expertise.
Our breadth is organised around a single therapeutic field. This enables us to connect disciplines without losing disease-specific depth.
Osteoarthritis biology
Clinical development
Phenotypes & mechanistic stratification
Biomarkers & multi-omics
Imaging strategy
Clinical trial design
Statistics & estimands
Regulatory strategy
Advanced therapies
Commercial & market strategy
Due diligence
Programme rescue
How we engage
Advisory support built around the programme — not a standard consulting package.
We can resolve one defined question, support a major development milestone or remain alongside the leadership team throughout the programme.
Strategic project
A focused engagement addressing a defined scientific, clinical, regulatory or commercial question.
Advisory retainer
Ongoing senior access for regular programme review, document input and critical decisions.
Embedded advisory team
A tailored multidisciplinary group integrated into the programme for a defined stage.
Scientific advisory board
Design, constitution, chairmanship or participation in scientific and clinical advisory boards.
Fractional leadership
Senior external leadership without the immediate requirement for a full-time appointment.
Independent due diligence
Confidential assessment for investment, licensing, acquisition or portfolio prioritisation.
Confidential discussion
When the next decision could determine the future of the asset, specialist judgement matters.
Speak directly with our senior advisers about your osteoarthritis programme, development challenge or investment decision.
Initial discussions are confidential and non-promotional.